NKILT Therapeutics is a preclinical cell therapy biotech developing a novel off-the-shelf approach with proprietary and first-in-class engineered CIR™NK cells that target HLA-G, expressed in over 50% of hematologic and solid tumors. Our unique technology enhances NK cell potency and functional persistence to safely increase depth and duration of response, while improving scalability speed and patient access. We are developing a pipeline of assets to tackle leukemia and solid tumors, especially GI track cancers, Breast cancer and other solid tumors. Our in vitro and in vivo proof of concepts across multiple tumors lead us to build our path to IND to start clinical trials by 2028. Our unique off-the-shelf platform will allow us to address unmet medical needs in multiple solid tumors, with a scalable, accessible and profitable approach so more patients can live cancer-free.